Screener
Ocular Therapeutix OCUL Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Ocular Therapeutix in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Ocular Therapeutix’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 7:28 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-055256
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Selling and marketing | 16,577 | 14,148 |
| General and administrative | 20,006 | 16,348 |
| Total costs and operating expenses | 104,125 | 74,615 |
| Loss from operations | (93,340) | (63,917) |
| Other income (expense): | ||
| Interest income | 6,050 | 3,826 |
| Interest expense | (2,777) | (2,984) |
| Change in fair value of derivative liabilities | 1,455 | (978) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Ocular Therapeutix's operating income?
- Ocular Therapeutix (OCUL) reported operating income of -$93.34M in Q1 2026.
- How has Ocular Therapeutix's operating income changed year-over-year?
- Ocular Therapeutix's operating income decreased by 46.0% year-over-year, from -$63.92M to -$93.34M.
- What is the long-term trend for Ocular Therapeutix's operating income?
- Over 4 years (2021 to 2025), Ocular Therapeutix's operating income has grown at a 36.4% compound annual growth rate (CAGR), from -$78.04M to -$270.02M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Ocular Therapeutix's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude